ACHIEVE

2024

IL-32 production from lung adenocarcinoma cells is potentially involved in immunosuppressive microenvironment.

Zhao S, Li L, Komohara Y, Matsubara E, Shinchi Y, Adawy A, Yano H, Pan C, Fujiwara Y, Ikeda K, Suzu S, Hibi T, Suzuki M.

Med Mol Morphol., in press. 

​

Dysfunction of sinus macrophages in tumor-bearing host induces resistance to immunotherapy.

Anami T, Pan C, Fujiwara Y, Komohara Y, Yano H, Saito Y, Sugimoto M, Wakita D, Motoshima T, Murakami Y, Yatsuda J, Takahashi N, Suzu S, Asano K, Tamada K, Kamba T. Cancer Science, Jan;115(1):59-69, 2024

 

2023

iPS cell-derived model to study the interaction between tissue macrophage and HIV-1. Eltalkhawy YM, Takahashi N, Ariumi Y, Shimizu J, Miyazaki K, Senju S, Suzu S. Journal of Leukocyte Biology 114: 53-67, 2023.

 

Potential involvement of IL-32 in cell-to-cell communication between macrophages and hepatoblastoma.

Adawy A, Li L, Hirao H, Irie T, Yoshii D, Yano H, Fujiwara Y, Esumi S, Honda M, Suzu S, Komohara Y, Hibi T. Pediatr Surg Int. 39: 275, 2023.

 

2022 

Inhibitory and stimulatory effects of IL-32 on HIV-1 infcetion.

Nasser H, Takahashi N, Eltalkhawy YM, Reda O, Lotfi S, Nasu K, Sakuragi J, Suzu S. The Journal of Immunology, 209:970-978, 2022.

​

M-CSFR expression in the embryonal component of hepatoblastoma and cell-to-cell interaction between macrophages and hepatoblastoma.

Li L, Irie T, Yoshii D, Komohara Y, Fujiwara Y, Esumi S, Kadohisa M, Honda M, Suzu S, Matsuura T, Kohashi K, Oda Y, Hibi T.   Medical Molecular Morphology, in press.

​

IL-34 in hepatoblastoma cells potentially promote tumor progression via autocrine and paracrine mechanisms. 

Irie T, Yoshii D, Komohara Y, Fujiwara Y, Kadohisa M, Honda M, Suzu S, Matsuura T, Kohashi K, Oda Y, Hibi T. Cancer Medicine 11(6): 1441-1453, 2022.

​

2021

M-Sec induced by HTLV-1 mediates an efficient viral transmission.

Hiyoshi M, Takahashi N, Eltalkhawy YM, Noyori O, Lotfi S, Panaampon J, Okada S, Tanaka Y, Ueno T, Fujisawa J, Sato Y, Suzuki T, Hasegawa H, Tokunaga M, Satou Y, Yasunaga J, Matsuoka M, Utsunomiya A, Suzu S.  PLoS Pathogens 2021, 17 (11): e1010126.

 

2020

Establishment of bone marrow-derived M-CSF receptor-dependent self-renewing macrophages.

Nasser H, Adhikary P, Abdel-Daim A, Noyori O, Panaampon J, Kariya R, Okada S, Ma W, Baba M, Takizawa H, Yamane M, Niwa H, Suzu S.
Cell Death Discovery 6: 63, 2020.

 

M-Sec facilitates intercellular transmission of HIV-1 through multiple mechanisms.

Lotfi S, Nasser H, Noyori O, Hiyoshi M, Takeuchi H, Koyanagi Y, Suzu S. Retrovirology 17: 20, 2020.

​

2019

Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.

Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, Kimura F.Blood 134 (10): 814-825,2019.

​

Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma.

Noyori O, Komohara Y, Nasser H, Hiyoshi M, Ma C, Pan C, Carreras J, Nakamura N, Sato A, Ando K, Okuno Y, Nosaka K, Matsuoka M,Suzu S. Clinical & Translational Immunology 8 (8): e1074, 2019.

​

2018

Apolipoprotein E is an HIV-1-inducible inhibitor of viral production and infectivity in macrophages.

Siddiqui R, Suzu S*, Ueno M, Nasser H, Koba R, Bhuyan F, Noyori O, Hamidi S, Sheng G, Yasuda-Inoue M, Hishiki T, Sukegawa S, Miyagi E, Strebel K, Matsushita S, Shimotohno K, Ariumi Y* .PLoS Pathogens 14 (11): e1007372, 2018.

 

2017

Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.

Maekawa T*, Osawa Y, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Kawamura T, Horiuchi T, Saga R, Kato S, Yamamura T, Watanabe J, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Kimura F. Leukemia 31: 2709-2716, 2017.

 

2016

Potential Role of the Formation of Tunneling Nanotubes in HIV-1 Spread in Macrophages.

Hashimoto M, Bhuyan F, Hiyoshi M, Noyori O, Nasser H, Miyazaki M, Saito T, Kondoh Y, Osada H, Kimura S, Hase K, Ohno H, Suzu S.

J Immunol. 2016 Feb 15;196(4):1832-41. doi: 10.4049/jimmunol.1500845. Epub 2016 Jan 15.

​

2011~2015

ATP generation in a host cell in early-phase infection is increased by upregulation of cytochrome c oxidase activity via the p2 peptide from human immunodeficiency virus type 1 Gag.

Ogawa M, Takemoto Y, Sumi S, Inoue D, Kishimoto N, Takamune N, Shoji S, Suzu S, Misumi S.

Retrovirology. 2015 Nov 17;12:97. doi: 10.1186/s12977-015-0224-y.

 

Fibrocytes Differ from Macrophages but Can Be Infected with HIV-1.

Hashimoto M, Nasser H, Bhuyan F, Kuse N, Satou Y, Harada S, Yoshimura K, Sakuragi J, Monde K, Maeda Y, Welbourn S, Strebel K, Abd El-Wahab EW, Miyazaki M, Hattori S, Chutiwitoonchai N, Hiyoshi M, Oka S, Takiguchi M, Suzu S.

J Immunol. 2015 Nov 1;195(9):4341-50. doi: 10.4049/jimmunol.1500955. Epub 2015 Sep 28.

 

The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.

Komohara Y, Morita T, Annan DA, Horlad H, Ohnishi K, Yamada S, Nakayama T, Kitada S, Suzu S, Kinoshita I, Dosaka-Akita H, Akashi K, Takeya M, Jinushi M.

Cancer Immunol Res. 2015 Sep;3(9):999-1007. doi: 10.1158/2326-6066.CIR-14-0156. Epub 2015 Mar 17.

 

Macropinocytosis and TAK1 mediate anti-inflammatory to pro-inflammatory macrophage differentiation by HIV-1 Nef.

Hashimoto M, Nasser H, Chihara T, Suzu S.

Cell Death Dis. 2014 May 29;5:e1267. doi: 10.1038/cddis.2014.233.

 

M-CSF inhibits anti-HIV-1 activity of IL-32, but they enhance M2-like phenotypes of macrophages.

Osman A, Bhuyan F, Hashimoto M, Nasser H, Maekawa T, Suzu S.

J Immunol. 2014 Jun 1;192(11):5083-9. doi: 10.4049/jimmunol.1302732. Epub 2014 Apr 18.

 

Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells.

Yamashina T, Baghdadi M, Yoneda A, Kinoshita I, Suzu S, Dosaka-Akita H, Jinushi M.

Cancer Res. 2014 May 15;74(10):2698-709. doi: 10.1158/0008-5472.CAN-13-2169. Epub 2014 Mar 17.

 

M-CSF receptor mutations in hereditary diffuse leukoencephalopathy with spheroids impair not only kinase activity but also surface expression.

Hiyoshi M, Hashimoto M, Yukihara M, Bhuyan F, Suzu S.

Biochem Biophys Res Commun. 2013 Nov 1;440(4):589-93. doi: 10.1016/j.bbrc.2013.09.141. Epub 2013 Oct 10.

 

HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway.

Kariya R, Taura M, Suzu S, Kai H, Katano H, Okada S.

Cancer Lett. 2014 Jan 1;342(1):52-9. doi: 10.1016/j.canlet.2013.08.045. Epub 2013 Sep 5.

 

Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins.

Chutiwitoonchai N, Hiyoshi M, Hiyoshi-Yoshidomi Y, Hashimoto M, Tokunaga K, Suzu S.

Microbes Infect. 2013 Apr;15(4):280-90. doi: 10.1016/j.micinf.2012.12.003. Epub 2013 Jan 30.

 

Importance of direct macrophage-tumor cell interaction on progression of human glioma.

Komohara Y, Horlad H, Ohnishi K, Fujiwara Y, Bai B, Nakagawa T, Suzu S, Nakamura H, Kuratsu J, Takeya M.

Cancer Sci. 2012 Dec;103(12):2165-72. doi: 10.1111/cas.12015. Epub 2012 Oct 26.

 

HIV-1 proteins preferentially activate anti-inflammatory M2-type macrophages.

Chihara T, Hashimoto M, Osman A, Hiyoshi-Yoshidomi Y, Suzu I, Chutiwitoonchai N, Hiyoshi M, Okada S, Suzu S.

J Immunol. 2012 Apr 15;188(8):3620-7. doi: 10.4049/jimmunol.1101593. Epub 2012 Mar 9.

 

The identification of a small molecule compound that reduces HIV-1 Nef-mediated viral infectivity enhancement.

Chutiwitoonchai N, Hiyoshi M, Mwimanzi P, Ueno T, Adachi A, Ode H, Sato H, Fackler OT, Okada S, Suzu S.

PLoS One. 2011;6(11):e27696. doi: 10.1371/journal.pone.0027696. Epub 2011 Nov 15.

 

Effects of naturally-arising HIV Nef mutations on cytotoxic T lymphocyte recognition and Nef's functionality in primary macrophages.

Mwimanzi P, Hasan Z, Hassan R, Suzu S, Takiguchi M, Ueno T.

Retrovirology. 2011 Jun 22;8:50. doi: 10.1186/1742-4690-8-50.

 

HIV-1 Nef perturbs the function, structure, and signaling of the Golgi through the Src kinase Hck.

Hiyoshi M, Takahashi-Makise N, Yoshidomi Y, Chutiwitoonchai N, Chihara T, Okada M, Nakamura N, Okada S, Suzu S.

J Cell Physiol. 2012 Mar;227(3):1090-7. doi: 10.1002/jcp.22825.

 

Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma.

Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, Takeya M.

Cancer Sci. 2011 Jul;102(7):1424-31. doi: 10.1111/j.1349-7006.2011.01945.x. Epub 2011 May 9.

 

Comparative study of human hematopoietic cell engraftment into BALB/c and C57BL/6 strain of rag-2/jak3 double-deficient mice.

Ono A, Hattori S, Kariya R, Iwanaga S, Taura M, Harada H, Suzu S, Okada S.

J Biomed Biotechnol. 2011;2011:539748. doi: 10.1155/2011/539748. Epub 2011 Jan 26.

​

2006~2010

Small molecule inhibition of HIV-1-induced MHC-I down-regulation identifies a temporally regulated switch in Nef action.

Dikeakos JD, Atkins KM, Thomas L, Emert-Sedlak L, Byeon IJ, Jung J, Ahn J, Wortman MD, Kukull B, Saito M, Koizumi H, Williamson DM, Hiyoshi M, Barklis E, Takiguchi M, Suzu S, Gronenborn AM, Smithgall TE, Thomas G.

Mol Biol Cell. 2010 Oct 1;21(19):3279-92. doi: 10.1091/mbc.E10-05-0470. Epub 2010 Aug 11.

 

Hybrid liposomes inhibit the growth of cholangiocarcinoma by induction of cell cycle arrest in G1 phase.

Towata T, Komizu Y, Kariya R, Suzu S, Matsumoto Y, Kobayashi N, Wongkham C, Wongkham S, Ueoka R, Okada S.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3680-2. doi: 10.1016/j.bmcl.2010.04.091. Epub 2010 Apr 27.

 

IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation.

Chihara T, Suzu S, Hassan R, Chutiwitoonchai N, Hiyoshi M, Motoyoshi K, Kimura F, Okada S.

Cell Death Differ. 2010 Dec;17(12):1917-27. doi: 10.1038/cdd.2010.60. Epub 2010 May 21.

 

Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB.

Seubwai W, Vaeteewoottacharn K, Hiyoshi M, Suzu S, Puapairoj A, Wongkham C, Okada S, Wongkham S.

Cancer Sci. 2010 Jul;101(7):1590-5. doi: 10.1111/j.1349-7006.2010.01572.x. Epub 2010 Mar 24.

 

Highly selective fusion and accumulation of hybrid liposomes into primary effusion lymphoma cells along with induction of apoptosis.

Towata T, Komizu Y, Suzu S, Ueoka R, Okada S.

Biochem Biophys Res Commun. 2010 Mar 12;393(3):445-8. doi: 10.1016/j.bbrc.2010.02.016. Epub 2010 Feb 6.

 

Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.

Dessouki O, Kamiya Y, Nagahama H, Tanaka M, Suzu S, Sasaki Y, Okada S.

Biochem Biophys Res Commun. 2010 Mar 5;393(2):331-7. doi: 10.1016/j.bbrc.2010.02.008. Epub 2010 Feb 6.

 

Hybrid liposomes inhibit the growth of primary effusion lymphoma in vitro and in vivo.

Towata T, Komizu Y, Suzu S, Matsumoto Y, Ueoka R, Okada S.

Leuk Res. 2010 Jul;34(7):906-11. doi: 10.1016/j.leukres.2009.12.010. Epub 2010 Jan 13.

 

Therapeutic effects of γ-irradiation in a primary effusion lymphoma mouse model.

Shiraishi Y, Gotoh K, Towata T, Shimasaki T, Suzu S, Kojima A, Okada S.

Exp Ther Med. 2010 Jan;1(1):79-84. Epub 2010 Jan 1.

 

Dys-regulated activation of a Src tyroine kinase Hck at the Golgi disturbs N-glycosylation of a cytokine receptor Fms.

Hassan R, Suzu S, Hiyoshi M, Takahashi-Makise N, Ueno T, Agatsuma T, Akari H, Komano J, Takebe Y, Motoyoshi K, Okada S.

J Cell Physiol. 2009 Nov;221(2):458-68. doi: 10.1002/jcp.21878.

 

Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.

Hattori S, Ide K, Nakata H, Harada H, Suzu S, Ashida N, Kohgo S, Hayakawa H, Mitsuya H, Okada S.

Antimicrob Agents Chemother. 2009 Sep;53(9):3887-93. doi: 10.1128/AAC.00270-09. Epub 2009 Jun 22.

 

Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway.

Takahashi-Makise N, Suzu S, Hiyoshi M, Ohsugi T, Katano H, Umezawa K, Okada S.

Int J Cancer. 2009 Sep 15;125(6):1464-72. doi: 10.1002/ijc.24521.

 

Ephedrae herba, a component of Japanese herbal medicine Mao-to, efficiently activates the replication of latent human immunodeficiency virus type 1 (HIV-1) in a monocytic cell line.

Murakami T, Harada H, Suico MA, Shuto T, Suzu S, Kai H, Okada S.

Biol Pharm Bull. 2008 Dec;31(12):2334-7.

 

Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3null mice intrahepatic engrafted with cord blood-derived CD34 + cells.

Okada S, Harada H, Ito T, Saito T, Suzu S.

Int J Hematol. 2008 Dec;88(5):476-82. doi: 10.1007/s12185-008-0215-z. Epub 2008 Nov 28.

 

Erythroblasts highly express the ABC transporter Bcrp1/ABCG2 but do not show the side population (SP) phenotype.

Yamamoto K, Suzu S, Yoshidomi Y, Hiyoshi M, Harada H, Okada S.

Immunol Lett. 2007 Nov 30;114(1):52-8. Epub 2007 Sep 17.

 

Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor.

Hiyoshi M, Suzu S, Yoshidomi Y, Hassan R, Harada H, Sakashita N, Akari H, Motoyoshi K, Okada S.

Blood. 2008 Jan 1;111(1):243-50. Epub 2007 Sep 24.

 

Proliferative activation up-regulates expression of CD4 and HIV-1 co-receptors on NK cells and induces their infection with HIV-1.

Harada H, Goto Y, Ohno T, Suzu S, Okada S.

Eur J Immunol. 2007 Aug;37(8):2148-55.

 

M-CSF-mediated macrophage differentiation but not proliferation is correlated with increased and prolonged ERK activation.

Suzu S, Hiyoshi M, Yoshidomi Y, Harada H, Takeya M, Kimura F, Motoyoshi K, Okada S.

J Cell Physiol. 2007 Aug;212(2):519-25.

 

2001~2005

Selective expansion and engraftment of human CD16+ NK cells in NOD/SCID mice.

Harada H, Suzu S, Ito T, Okada S.

Eur J Immunol. 2005 Dec;35(12):3599-609.

 

BT-IgSF, a novel immunoglobulin superfamily protein, functions as a cell adhesion molecule.

Harada H, Suzu S, Hayashi Y, Okada S.

J Cell Physiol. 2005 Sep;204(3):919-26.

 

HIV-1 Nef interferes with M-CSF receptor signaling through Hck activation and inhibits M-CSF bioactivities.

Suzu S, Harada H, Matsumoto T, Okada S.

Blood. 2005 Apr 15;105(8):3230-7. Epub 2004 Dec 30.

​

Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.

J Biol Chem. 2003 Aug 29;278(35):32892-8. Epub 2003 Jun 18.

 

Cloning and characterization of a novel RING-B-box-coiled-coil protein with apoptotic function.

Kimura F, Suzu S, Nakamura Y, Nakata Y, Yamada M, Kuwada N, Matsumura T, Yamashita T, Ikeda T, Sato K, Motoyoshi K.

J Biol Chem. 2003 Jul 4;278(27):25046-54. Epub 2003 Apr 10.

 

Molecular cloning of a novel immunoglobulin superfamily gene preferentially expressed by brain and testis.

Suzu S, Hayashi Y, Harumi T, Nomaguchi K, Yamada M, Hayasawa H, Motoyoshi K.

Biochem Biophys Res Commun. 2002 Sep 6;296(5):1215-21.

 

Effect of coadministration of M-CSF and IFN-alpha on NK1.1+ cells in mice.

Sakurai T, Misawa E, Tanaka-Douzono M, Hagesita H, Nomaguchi K, Tetsuya K, Suzu S, Yamada M, Hayasawa H, Motoyoshi K.

J Interferon Cytokine Res. 2002 Jun;22(6):701-8.

 

Signal transduction in macrophages: negative regulation for macrophage colony-stimulating factor receptor signaling.

Suzu S, Motoyoshi K.

Int J Hematol. 2002 Jul;76(1):1-5. Review.

 

Detection of murine adult bone marrow stroma-initiating cells in Lin(-)c-fms(+)c-kit(low)VCAM-1(+) cells.

Tanaka-Douzono M, Suzu S, Yamada M, Wakimoto N, Hayasawa H, Hatake K, Motoyoshi K.

J Cell Physiol. 2001 Oct;189(1):45-53.

 

Expression of Jagged1 gene in macrophages and its regulation by hematopoietic growth factors.

Nomaguchi K, Suzu S, Yamada M, Hayasawa H, Motoyoshi K.

Exp Hematol. 2001 Jul;29(7):850-5.

 

Antitumor immunity induced by irradiated tumor cells producing macrophage colony-stimulating factor.

Suzu S, Kimura F, Tanaka-Douzono M, Yamada M, Nakamura Y, Wakimoto N, Sato K, Morita T, Ikeda K, Motoyoshi K.

Int J Hematol. 2001 Apr;73(3):378-82.

 

Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis.

Suzuki M, Takamizawa S, Nomaguchi K, Suzu S, Yamada M, Igarashi T, Sato I.

Br J Haematol. 2001 Apr;113(1):49-51.

 

 

1996~2000

p56(dok-2) as a cytokine-inducible inhibitor of cell proliferation and signal transduction.

Suzu S, Tanaka-Douzono M, Nomaguchi K, Yamada M, Hayasawa H, Kimura F, Motoyoshi K.

EMBO J. 2000 Oct 2;19(19):5114-22.

 

Effect of cytokines on the proliferation/differentiation of stroma-initiating cells.

Yamada M, Suzu S, Tanaka-Douzono M, Wakimoto N, Hatake K, Hayasawa H, Motoyoshi K.

J Cell Physiol. 2000 Sep;184(3):351-5.

 

Association of Cbl with Fms and p85 in response to macrophage colony-stimulating factor.

Ota J, Sato K, Kimura F, Wakimoto N, Nakamura Y, Nagata N, Suzu S, Yamada M, Shimamura S, Motoyoshi K.

FEBS Lett. 2000 Jan 21;466(1):96-100.

 

In vivo stimulatory effect of macrophage colony-stimulating factor on the number of stroma-initiating cells.

Tanaka-Douzono M, Suzu S, Yamada M, Misawa E, Wakimoto N, Shimamura S, Hatake K, Motoyoshi K.

J Cell Physiol. 1999 Feb;178(2):267-73.

 

Association of CrkL with STAT5 in hematopoietic cells stimulated by granulocyte-macrophage colony-stimulating factor or erythropoietin.

Ota J, Kimura F, Sato K, Wakimoto N, Nakamura Y, Nagata N, Suzu S, Yamada M, Shimamura S, Motoyoshi K.

Biochem Biophys Res Commun. 1998 Nov 27;252(3):779-86.

 

Identification of alternatively spliced transcripts encoding murine macrophage colony-stimulating factor.

Suzu S, Hatake K, Ota J, Mishima Y, Yamada M, Shimamura S, Kimura F, Motoyoshi K.

Biochem Biophys Res Commun. 1998 Apr 7;245(1):120-6.

 

Properties of primary murine stroma induced by macrophage colony-stimulating factor.

Yamada M, Suzu S, Akaiwa E, Wakimoto N, Hatake K, Motoyoshi K, Shimamura S.

J Cell Physiol. 1997 Oct;173(1):1-9.

 

Biologic activity of proteoglycan macrophage colony-stimulating factor.

Suzu S, Kimura F, Ota J, Motoyoshi K, Itoh T, Mishima Y, Yamada M, Shimamura S.

J Immunol. 1997 Aug 15;159(4):1860-7.

 

Identification of binding domains for basic fibroblast growth factor in proteoglycan macrophage colony-stimulating factor.

Suzu S, Kimura F, Matsumoto H, Yamada M, Hashimoto K, Shimamura S, Motoyoshi K.

Biochem Biophys Res Commun. 1997 Jan 13;230(2):392-7.

 

 

1990〜1995

Immunohistochemical identification of proteoglycan form of macrophage colony-stimulating factor on bone surface.

Ohtsuki T, Hatake K, Suzu S, Saito K, Motoyoshi K, Miura Y.

Calcif Tissue Int. 1995 Sep;57(3):213-7.

 

Augmentation of cancer chemotherapy by preinjection of human macrophage colony-stimulating factor in L1210 leukemic cell-inoculated mice.

Douzono M, Suzu S, Yamada M, Yanai N, Kawashima T, Hatake K, Motoyoshi K.

Jpn J Cancer Res. 1995 Mar;86(3):315-21.

 

Proteoglycan form of macrophage colony-stimulating factor binds low density lipoprotein.

Suzu S, Inaba T, Yanai N, Kawashima T, Yamada N, Oka T, Machinami R, Ohtsuki T, Kimura F, Kondo S, et al.

J Clin Invest. 1994 Oct;94(4):1637-41.

 

Structural analysis of proteoglycan macrophage colony-stimulating factor.

Kimura F, Suzu S, Nakamura Y, Wakimoto N, Kanatani Y, Yanai N, Nagata N, Motoyoshi K.

J Biol Chem. 1994 Aug 5;269(31):19751-6.

 

Quantitative analysis of the two macrophage colony-stimulating factor mRNA expressed in a human stromal cell line by reverse transcription-polymerase chain reaction (RT-PCR).

Ohtsuki T, Ikeda M, Hatake K, Tomizuka H, Hoshino Y, Suzu S, Harigaya K, Motoyoshi K, Miura Y.

Biochim Biophys Acta. 1994 Jun 30;1222(2):141-6.

 

Direct interaction of proteoglycan macrophage colony-stimulating factor and basic fibroblast growth factor.

Suzu S, Kimura F, Yamada M, Yanai N, Kawashima T, Nagata N, Motoyoshi K.

Blood. 1994 Jun 1;83(11):3113-9.

 

Effects of 1 alpha,25-dihydroxyvitamin D3 on macrophage colony-stimulating factor production and proliferation of human monocytic cells.

Kaneki M, Inoue S, Hosoi T, Mizuno Y, Akedo Y, Ikegami A, Nakamura T, Shiraki M, Ito H, Suzu S, et al.

Blood. 1994 Apr 15;83(8):2285-93.

 

Alteration of the proteoglycan form of macrophage colony-stimulating factor produced by a human stromal line stimulated by tumor necrosis factor-alpha.

Ohtsuki T, Hatake K, Suzu S, Harigaya K, Miura Y, Motoyoshi K.

Exp Hematol. 1994 Apr;22(4):366-9.

​

Induction of tumor necrosis factor in mice by recombinant human macrophage colony-stimulating factor.

Sakurai T, Suzu S, Yamada M, Yanai N, Kawashima T, Hatake K, Takaku F, Motoyoshi K.

Jpn J Cancer Res. 1994 Jan;85(1):80-5.

 

Binding of membrane-anchored macrophage colony-stimulating factor (M-CSF) to its receptor mediates specific adhesion between stromal cells and M-CSF receptor-bearing hematopoietic cells.

Uemura N, Ozawa K, Takahashi K, Tojo A, Tani K, Harigaya K, Suzu S, Motoyoshi K, Matsuda H, Yagita H, et al.

Blood. 1993 Nov 1;82(9):2634-40.

 

A proteoglycan form of macrophage colony-stimulating factor that binds to bone-derived collagens and can be extracted from bone matrix.

Ohtsuki T, Suzu S, Hatake K, Nagata N, Miura Y, Motoyoshi K.

Biochem Biophys Res Commun. 1993 Jan 15;190(1):215-22.

 

A human osteoblastic cell line, MG-63, produces two molecular types of macrophage-colony-stimulating factor.

Ohtsuki T, Suzu S, Nagata N, Motoyoshi K.

Biochim Biophys Acta. 1992 Sep 9;1136(3):297-301.

 

Biological activity of a proteoglycan form of macrophage colony-stimulating factor and its binding to type V collagen.

Suzu S, Ohtsuki T, Makishima M, Yanai N, Kawashima T, Nagata N, Motoyoshi K.

J Biol Chem. 1992 Aug 25;267(24):16812-5.

 

Identification of a high molecular weight macrophage colony-stimulating factor as a glycosaminoglycan-containing species.

Suzu S, Ohtsuki T, Yanai N, Takatsu Z, Kawashima T, Takaku F, Nagata N, Motoyoshi K.

J Biol Chem. 1992 Mar 5;267(7):4345-8.

 

Granulocyte colony-stimulating factor-producing malignant lymphoma.

Ohtsuki T, Matsu-ura Y, Suzu S, Mizukami H, Ohnishi M, Kimura F, Nagata N, Motoyoshi K.

Acta Haematol. 1992;87(3):156-9.

 

Characterization of macrophage colony-stimulating factor in body fluids by immunoblot analysis.

Suzu S, Yanai N, Sato-Somoto Y, Yamada M, Kawashima T, Hanamura T, Nagata N, Takaku F, Motoyoshi K.

Blood. 1991 May 15;77(10):2160-5.

 

Enhancement of the antibody-dependent tumoricidal activity of human monocytes by human monocytic colony-stimulating factor.

Suzu S, Yanai N, Saito M, Kawashima T, Kasahara T, Saito M, Takaku F, Motoyoshi K.

Jpn J Cancer Res. 1990 Jan;81(1):79-84.

 

 

~1989

Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity.

Suzu S, Yokota H, Yamada M, Yanai N, Saito M, Kawashima T, Saito M, Takaku F, Motoyoshi K.

Cancer Res. 1989 Nov 1;49(21):5913-7.

 

 

Differences in bovine parainfluenza 3 virus variants studied by sequencing of the genes of viral envelope proteins.

Shioda T, Wakao S, Suzu S, Shibuta H.

Virology. 1988 Feb;162(2):388-96.

 

Nucleotide sequence of the bovine parainfluenza 3 virus genome: the genes of the F and HN glycoproteins.

Suzu S, Sakai Y, Shioda T, Shibuta H.

Nucleic Acids Res. 1987 Apr 10;15(7):2945-58.

 

Nucleotide sequence of the bovine parainfluenza 3 virus genome: its 3' end and the genes of NP, P, C and M proteins.

Sakai Y, Suzu S, Shioda T, Shibuta H.

Nucleic Acids Res. 1987 Apr 10;15(7):2927-44.

 

Differences in bovine parainfluenza 3 virus variants studied by monoclonal antibodies against viral glycoproteins.

Shibuta H, Suzu S, Shioda T.

Virology. 1986 Dec;155(2):688-96.